Chua Su-Kiat, Lo Huey-Ming, Chiu Chiung-Zuan, Shyu Kou-Gi
Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Division of Cardiology, Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
Nephrology (Carlton). 2016 Jul;21(7):583-91. doi: 10.1111/nep.12653.
CHA2 DS2 -VASc score has been proven to have great prognostic value in patients with acute coronary syndrome (ACS). We aimed to determine whether the addition of renal dysfunction in the CHA2 DS2 -VASc score would improve the prognostic impact of the scoring system to predict prognosis among ACS patients.
A total of 3031 ACS patients were prospectively enrolled at 39 hospitals and followed for 1 year. The patients were divided into three groups based on estimated glomerular filtration rate (eGFR) (group 1, eGFR>90; group 2, eGFR between 60 and 90; and group 3, eGFR<60 mL/min per 1.73 m(2) ). The occurrence of subsequent myocardial infarction (MI), stroke, or death was recorded.
As renal function progressively decreased from group 1 to 3, the patients were, respectively older and had higher incidence of comorbidity, worse Killip classification, and less evidence-based medical therapies. The rate of subsequent MI, stroke or death increased from 3.4% in group 1 to 7.4% in group 2 and 17.2% in group 3 (P < 0.001). Renal dysfunction (eGFR<60 mL/min per 1.73 m(2) ) and CHA2 DS2 -VASc scores were both significant predictors of adverse events in multivariable regression analyses. Renal dysfunction can further stratify patients with CHA2 DS2 -VASc score of 0 or 1 into 3 groups with different adverse event rates (group 1, 3.0%; group 2, 4.1%; and group 3, 9.2%, P < 0.001). A new scoring system (R-CHA2 DS2 -VASc score) derived by assigning one more point for eGFR ≤ 60 mL/min per 1.73 m(2) to the CHA2 DS2 -VASc score could improve its predictive accuracy (area under the receiver operating curve, 0.70 vs. 0.66, P < 0.001).
Renal dysfunction is a significant risk factor of future adverse events in ACS patients and may improve the prognostic impact of the CHA2 DS2 -VASc score.
CHA2 DS2 -VASc评分已被证明在急性冠状动脉综合征(ACS)患者中具有很大的预后价值。我们旨在确定在CHA2 DS2 -VASc评分中加入肾功能不全是否会提高该评分系统预测ACS患者预后的预后影响。
前瞻性纳入39家医院的3031例ACS患者,并随访1年。根据估计肾小球滤过率(eGFR)将患者分为三组(第1组,eGFR>90;第2组,eGFR在60至90之间;第3组,eGFR<60 mL/min per 1.73 m²)。记录随后发生的心肌梗死(MI)、中风或死亡情况。
随着肾功能从第1组到第3组逐渐下降,患者年龄分别增大,合并症发生率更高,Killip分级更差,循证医学治疗更少。随后发生MI、中风或死亡的比率从第1组的3.4%增至第2组的7.4%和第3组的17.2%(P<0.001)。在多变量回归分析中,肾功能不全(eGFR<60 mL/min per 1.73 m²)和CHA2 DS2 -VASc评分均是不良事件的显著预测因素。肾功能不全会将CHA2 DS2 -VASc评分为0或1的患者进一步分为不良事件发生率不同的三组(第1组,3.0%;第2组,4.1%;第3组,9.2%,P<0.001)。通过给CHA2 DS2 -VASc评分中eGFR≤60 mL/min per 1.73 m²的患者再加1分得出的新评分系统(R-CHA2 DS2 -VASc评分)可提高其预测准确性(受试者工作特征曲线下面积,0.70对0.66,P<0.001)。
肾功能不全是ACS患者未来发生不良事件的重要危险因素,可能会提高CHA2 DS2 -VASc评分的预后影响。